Navigation Links
Medizone International's Mass-Market Sterilization Technology to be Produced by Canadian Medical Device Heavyweights
Date:1/19/2011

SAN FRANCISCO, Jan. 19, 2011 /PRNewswire/ -- Medizone International, Inc. (OTC Bulletin Board: MZEI) (OTCQB: MZEI) announced today that it has entered into a final product development and production agreement for the manufacture of its AsepticSure™ Advanced Oxidative Sterilization Processes, with ADA Innovations of Toronto, Canada.

Edwin Marshall, CEO of Medizone, commented, "Purely from a corporate perspective, ADA is a 'new kid on the block' - but what the development team behind it brings to the table for the future of AsepticSure™, exceeds all of our expectations."

ADA founders and directors, Mark Costa B.A. Sc Mechanical Engineering and Hao (Hawk) Chen M.S. Biomedical Engineering, bring more than 20 years of high-level experience to this project from the top echelons of industry – both in the engineering and medical device sectors.

Datascope Patient Monitoring (now Mindray North America), Husky, along with global medical device manufacturing giant, Mindray International, are just three of the big-name corporations on Mark and Hawk's respective resumes. Others of significance include; Vasogen and Hologic.

Marshall  commented, "After short-listing five potential manufacturing partners – each with impressive backgrounds in medical device development – ADA stood out as a logical choice for us, for two reasons: They were the only group who boasted a depth of knowledge in Ozone based technologies AND experience in medical device design, building and product launch."

Dr Michael Shannon, Medizone's Director of Medical affairs, added, "The dual qualifications that ADA brings to this collaborative venture are not only unique in the medical device industry, but are also essential to the achievement of our end-goal i.e. the mass production of a device that satisfies all design and operational requirements pertaining to any relevant market sector, anywhere on the planet."

Edwin Marshall went on to say, "ADA Innovations provides a perfect fit of knowledge, expertise and experience for bringing the AsepticSure™ systems to market."

"From a compliance point of view", said Marshall, "our relationship with ADA ensures that the design, content and manufacturing standards of the production units will be regulatory-compliant, not only in North America, but also in the lucrative UK and EU markets."

"Given that the stringent green regulations applicable to these two regions are some of the toughest in the world, it's reassuring to say the least," said Marshall, "that ADA can seamlessly tailor location-specific unit designs to meet and comply with local regulatory standards."

The AsepticSure™ final-phase development program, already underway, can be broken down into four primary, progressive steps as follows:

  • Completion of final commercial design and verification
  • Regional regulatory compliance
  • Soft product launch involving small scale manufacturing output
  • Multi-sector market penetration supported by up-scaled output and the ability to outsource macro manufacturing capacity at the appropriate time

  • "While the transition from beta to production equipment has taken significantly longer than anticipated a year ago, the 'wait', as they say, 'has been well worth it', said Marshall.  "We're now more confident than ever that our AsepticSure™ product line will far surpass any other form of sterilization technology on the market – not only in terms of its clinically proven anti-microbial efficacy, but also in its functionality, mobility and cost-effectiveness."For press information on Medizone, please contact:Jack Eversull, Investor Relations, The Eversull Group, Inc.T: 001-972-571-1624F: 001-214-469-2361E: jack@theeversullgroup.comMedizone International, Inc. is a research and development company engaged in developing its AsepticSure™ System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, patient rooms, schools, clean rooms and other critical infrastructure. A government variant is being developed for bio-terrorism countermeasures with additional variants for sports facilities and food processing applications.

    This Press Release may contain certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues, the financial requirements of the company to achieve its business objectives, and the need for possible additional funding. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

    For more information, visit: www.medizoneint.com or email: operations@medizoneint.com


    '/>"/>
    SOURCE Medizone International, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Medizone International Files For Additional Bio-Terrorism Countermeasures Patent Protection
    2. Medizone International Announces Third Round of AsepticSure
    3. Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun
    4. Environmental Tectonics Corporations Sterilization Systems Group Awarded Major Contract
    5. Reportlinker Adds Global Sterilization Systems & Equipment Industry
    6. AsepticSure(TM) Hospital Sterilization System Demonstrates Total Eradication of Super Bugs
    7. Reportlinker Adds Sterilization Systems & Equipment - A Global Market Perspective
    8. BeamOne LLC to Add New Ebeam Sterilization Service Center
    9. Zyga Technology, Inc. Receives FDA 510(K) Clearance for the SImmetry™ Sacroiliac Joint Fusion System
    10. Weikang Bio-Technology Expects to Report Fiscal 2010 Revenue of $77.8 Million and Net Income of $31.2 Million or $1.04 Earnings per Share
    11. Emerging Markets Are Gaining Ground in Medical Technology Innovation; U.S. Maintains Lead, Finds PwCs Medical Technology Innovation Scorecard
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/19/2017)... NEW YORK , Jan. 19, 2017 ... studies the current and future scenario of the global ... for rising opioid consumption. Severe chronic constipation is a ... resistance to traditional laxatives. Hence, novel targeted therapy has ... of OIC sufferers, launch of targeted medicines, and growing ...
    (Date:1/19/2017)... 2017 According to a study conducted by ... to witness a CAGR of 6.5% during the forecast period 2016-2024. ... continue to be the leading market for cryotherapy globally during the ... Highlights ... ensuring affordable and adequate supply of gas in order to provide ...
    (Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
    Breaking Medicine Technology:
    (Date:1/21/2017)... Raton, FL (PRWEB) , ... January 21, 2017 , ... ... Germany, announced it is bringing its product to the United States as part of ... over the last 25 years, Alcovit aims to reduce the productions of nasty toxins ...
    (Date:1/21/2017)... ... , ... Seamild, the largest manufacturer of oats in China, is now aiming ... As Oat is recognized globally as one of the healthiest cereals, XieQingkui, the founder ... is a move to sow the seed of good karma. Buddhism spirit featuring benevolence ...
    (Date:1/21/2017)... Barbara, CA (PRWEB) , ... January 21, 2017 ... ... its Director of Alumni Relations, Dianne Travis-Teague, the electrifying line-up of events for ... festivities for alumni, family, friends, and community. “Coming Home 2017” will be ...
    (Date:1/21/2017)... (PRWEB) , ... January 21, 2017 , ... ... of its new medical office in Petaluma, located at 167 Lynch Creek Way. ... access to SRO sports medicine and rehabilitation services and on-site x-ray ...
    (Date:1/21/2017)... ... January 21, 2017 , ... The Nobel Biocare™ dental ... in media for its creos™ line of bone regenerative products. Specifically, the ... which he utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction ...
    Breaking Medicine News(10 mins):